These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
266 related articles for article (PubMed ID: 3855615)
1. [Tumor markers of pancreatic cancer]. Takami H; Hishinuma S; Shintoku J; Furuuchi T; Ogata Y; Abe O Gan To Kagaku Ryoho; 1985 Feb; 12(2):212-9. PubMed ID: 3855615 [TBL] [Abstract][Full Text] [Related]
2. [Diagnostic usefulness of serum levels of pancreatic oncofetal antigen (POA) and CA 19-9 in pancreatic cancers: monitoring of postoperative recurrences]. Takami H; Hishinuma S; Shintoku J; Ogata Y; Abe O Gan No Rinsho; 1985 May; 31(6 Suppl):631-7. PubMed ID: 3861883 [TBL] [Abstract][Full Text] [Related]
3. Multiparametric tumor marker (CA 19-9, CEA, AFP, POA) analyses of pancreatic juices and sera in pancreatic diseases. Schmiegel WH; Eberl W; Kreiker C; Kalthoff H; Bützow GH; Jessen K; Klapdor R; Soehendra N; Wargenau M; Classen M Hepatogastroenterology; 1985 Jun; 32(3):141-5. PubMed ID: 2410346 [TBL] [Abstract][Full Text] [Related]
4. [Diagnostic usefulness and limitation of measuring pancreatic cancer associate antigen, SPan-1, in patients with pancreatic cancer]. Satake K; Chung YS; Umeyama K; Takeuchi T; Kim YS Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):1139-46. PubMed ID: 2730018 [TBL] [Abstract][Full Text] [Related]
5. Tumor markers carbohydrate antigens CA 19-9 and CA-50 and carcinoembryonic antigen in pancreatic cancer and benign diseases of the pancreatobiliary tract. Harmenberg U; Wahren B; Wiechel KL Cancer Res; 1988 Apr; 48(7):1985-8. PubMed ID: 3349472 [TBL] [Abstract][Full Text] [Related]
6. [Value and limitations of neoplasm markers in the diagnosis of pancreatic carcinoma]. Fabris C; Basso D; Meggiato T; Del Favero G; Fogar P; Panozzo MP; Ferrara C; Scalon P; Naccarato R Recenti Prog Med; 1991 Mar; 82(3):166-72. PubMed ID: 2047559 [TBL] [Abstract][Full Text] [Related]
7. Usefulness of CEA, TPA, GICA, CA 72.4, and CA 195 in the Diagnosis of primary colorectal cancer and at its relapse. Nicolini A; Caciagli M; Zampieri F; Ciampalini G; Carpi A; Spisni R; Colizzi C Cancer Detect Prev; 1995; 19(2):183-95. PubMed ID: 7750106 [TBL] [Abstract][Full Text] [Related]
8. [The role of CEA, CA 19-9 and TPA in the diagnosis of pancreatic cancer. Evaluation by discriminant analysis]. Basso D; Fabris C; Del Favero G; Panucci A; Piccoli A; Plebani M; Pedrazzoli S; Baccaglini U; Lise M; Burlina A Minerva Med; 1986 Apr; 77(16):613-6. PubMed ID: 3458035 [TBL] [Abstract][Full Text] [Related]
9. Clinical evaluation of tissue polypeptide antigen (TPA) in the diagnosis of pancreatic carcinoma. Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttila I Anticancer Res; 1993; 13(5C):1883-7. PubMed ID: 8267397 [TBL] [Abstract][Full Text] [Related]
10. Estimation of carbohydrate antigen (CA) 19-9 levels in pure pancreatic juice of patients with pancreatic cancer. Nishida K; Tasaki N; Miyagawa H; Yoshikawa T; Kondo M Am J Gastroenterol; 1988 Feb; 83(2):126-9. PubMed ID: 3422536 [TBL] [Abstract][Full Text] [Related]
11. [Detection of DU-PAN-2 antigen (pancreatic cancer-associated antigen) in sera of patients with cancer of the digestive tract]. Takami H; Furuuchi T; Ogata Y; Abe O Gan To Kagaku Ryoho; 1986 Oct; 13(11):3207-14. PubMed ID: 3777958 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of serum pancreatic enzymes, carbohydrate antigen 19-9, and carcinoembryonic antigen in various pancreatic diseases. Satake K; Kanazawa G; Kho I; Chung Y; Umeyama K Am J Gastroenterol; 1985 Aug; 80(8):630-6. PubMed ID: 2411125 [TBL] [Abstract][Full Text] [Related]
13. Serum markers and clinical data in diagnosing pancreatic cancer: a contrastive approach. Fabris C; Del Favero G; Basso D; Piccoli A; Meggiato T; Angonese C; Plebani M; Leandro G; Burlina A; Naccarato R Am J Gastroenterol; 1988 May; 83(5):549-53. PubMed ID: 3163228 [TBL] [Abstract][Full Text] [Related]
14. [Evaluation of pancreatic oncofetal antigen (POA) in the diagnosis of pancreatic cancer]. Nishida K Gan To Kagaku Ryoho; 1983 Feb; 10(2 Pt 2):601-8. PubMed ID: 6349542 [TBL] [Abstract][Full Text] [Related]
15. [Pancreatic oncofetal antigen (POA)]. Mugitani H; Furue H; Kako M; Hirota F; Fuse K; Takahashi T; Sakamoto K; Yamada K; Suminaga M; Ezaki M; Judo R Gan To Kagaku Ryoho; 1983 Aug; 10(8):1737-43. PubMed ID: 6882002 [TBL] [Abstract][Full Text] [Related]
16. [Clinical utility of tumor markers in gastric and colon cancer]. Ogawa K; Naritaka Y; Koyama N; Ohtani Y; Kawata H; Yagawa H; Kajiwara T; Sakakibara N Gan No Rinsho; 1985 May; 31(6 Suppl):638-47. PubMed ID: 3861884 [TBL] [Abstract][Full Text] [Related]
17. Proliferation tissue polypeptide antigen distinguishes malignant mucinous cystadenocarcinomas from benign cystic tumors and pseudocysts. Yang JM; Southern JF; Warshaw AL; Lewandrowski KB Am J Surg; 1996 Jan; 171(1):126-9; discussion 129-30. PubMed ID: 8554126 [TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical staining of pancreatic cancer with CA19-9, KM01, unabsorbed CEA, and absorbed CEA. A comparison with normal pancreas and chronic pancreatitis. Shimizu M; Saitoh Y; Ohyanagi H; Itoh H Arch Pathol Lab Med; 1990 Feb; 114(2):195-200. PubMed ID: 1689141 [TBL] [Abstract][Full Text] [Related]
19. Tissue polypeptide antigen, galactosyltransferase isoenzyme II and pancreatic oncofetal antigen serum determination: role in pancreatic cancer diagnosis. Basso D; Fabris C; Panucci A; Del Favero G; Angonese C; Plebani M; Petrin P; Burlina A; Naccarato R Int J Pancreatol; 1988; 3 Suppl 1():S95-100. PubMed ID: 3145303 [TBL] [Abstract][Full Text] [Related]
20. [The L.A.I. test and tumor markers (Ca 19-9 and TPA) in the diagnosis of pancreatic carcinoma]. Meduri F; Bizzarini M; Diana F; Merenda R; Gerunda GE; Doni MG; Maffei Faccioli A Minerva Chir; 1989 Aug; 44(15-16):1777-81. PubMed ID: 2682370 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]